IDEXX Laboratories SEC Filings

IDEXX Laboratories Executive Vice President George Fennell exercised stock options and sold shares in recent transactions. On February 9 and 10, 2026, he exercised options covering 1,476 and 11,345 shares of common stock at an exercise price of $67.85 per share.

On February 10, 2026, Fennell then sold 11,345 shares of common stock in multiple open-market transactions at weighted average prices ranging from about $642.99 to $650.32 per share. After these trades, he directly beneficially owned 9,823 shares of IDEXX common stock.

A holder of IDEXX Laboratories common stock has filed a notice of proposed sale under Rule 144. The filing covers 11,345 shares of common stock, with an aggregate market value of 7,336,994.15, to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 02/10/2026.

These 11,345 shares were acquired on 02/10/2026 via a stock option exercise from the issuer, paid in cash on the same date. The filing notes that 79,851,330 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.

IDEXX Laboratories director Joseph L. Hooley acquired 36 deferred stock units of common stock on January 30, 2026 through the company’s Director Deferred Compensation Plan. The units were valued using a share price of $670.46, based on $24,375.00 of cash fees he elected to defer.

Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories common stock. The units vest immediately upon grant, but are only paid in shares after Hooley resigns from the board or on other fixed dates allowed under the plan. Following this grant, he beneficially owns 75 shares directly.

IDEXX Laboratories, Inc. filed a Form 8-K after announcing its financial results for the quarter and year ended December 31, 2025. The detailed results are provided in a press release furnished as Exhibit 99.1.

The company specifies that this earnings information is furnished under Item 2.02 of Form 8-K and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. The report is signed by Andrew Emerson, Executive Vice President, Chief Financial Officer and Treasurer.

IDEXX Laboratories is planning a CEO transition. Jonathan (Jay) Mazelsky will step down as President and Chief Executive Officer on May 12, 2026 and become Executive Chair of the Board until his planned retirement following the annual shareholder meeting in May 2027. Michael (Mike) Erickson, PhD, currently Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine, will become President and CEO and join the Board as a Class II director on the same date.

Erickson’s CEO terms include a $1,000,000 annual base salary, an annual bonus targeted at 120% of base salary, and a 2026 long‑term equity incentive with a target grant value of at least $7.8 million split between stock options and performance RSUs. His amended change‑in‑control agreement provides cash severance of up to three times salary and average bonus plus benefit continuations and accelerated vesting on time‑based equity after a qualifying change‑in‑control termination. Mazelsky, as Executive Chair, will receive a $1,150,000 base salary and an incentive structure tied to 2026 performance and a time‑vesting RSU grant with a target value of at least $8.275 million.

IDEXX Laboratories entered into Amendment No. 2 to its fourth amended and restated credit agreement, dated November 12, 2025. The amendment adds a three‑year term loan facility and extends the revolving credit facility maturity to five years from the closing date.

The credit arrangement now consists of an unsecured $1.0 billion revolver and an unsecured $250 million term loan, with flexibility to add up to $250 million in incremental revolving commitments and/or term loans. Borrowings may be used for general corporate purposes.

Interest is benchmarked to currencies and tenors selected, with margins tied to the consolidated leverage ratio: for U.S. dollars, base rate or Adjusted Term SOFR/Daily Simple SOFR with margins ranging from 0.0%–1.375%. Comparable benchmarks apply for CAD (PRIMCAN/Term CORRA), EUR (EURIBOR) and AUD (BBSY). Obligations are guaranteed by certain U.S. subsidiaries, with future material U.S. subsidiaries required to guarantee. Covenants include a consolidated leverage ratio and customary negative covenants; events of default are customary, including a change of control.

IDEXX Laboratories (IDXX): Executive Vice President reports option exercises and stock sales. On 11/07/2025, the officer exercised non-qualified stock options to acquire 7,125 shares at $288.78 and 5,405 shares at $505.53. The insider then sold 5,114 shares at a weighted average price of $702.2017, 1,465 shares at $703.7339, 1,468 shares at $704.8659, and 1,378 shares at $705.5448.

Following these transactions, the officer beneficially owned 21,148.9435 shares directly, plus 160 shares held indirectly jointly with spouse. Derivative holdings reported as remaining include 1,604 options. Footnotes note weighted-average sale prices with full breakdowns available upon request and prior vesting schedules for the exercised options.

IDEXX Laboratories (IDXX): Director Joseph L. Hooley reported the acquisition of 39 deferred stock units on 10/30/2025 under the company’s Director Deferred Compensation Plan, coded “A.” The filing lists a reference price of $628.54 per share and states the units were issued in exchange for deferred cash compensation of $24,375.00.

Each deferred stock unit represents a contingent right to receive one share of common stock. The units vest immediately upon grant and are payable as common stock following the director’s resignation from the Board or at other nondiscretionary dates allowed by the plan. Following the transaction, 39 shares are beneficially owned directly.

IDEXX Laboratories reported higher third‑quarter results in its Form 10‑Q for the period ended September 30, 2025. Total revenue rose to $1,105,239 thousand from $975,543 thousand a year ago, driven by the Companion Animal Group, where CAG Diagnostics recurring revenue reached $873,273 thousand. Product revenue was $656,159 thousand and service revenue was $449,080 thousand.

Gross profit increased to $683,354 thousand from $596,038 thousand. Net income grew to $274,610 thousand, with diluted EPS of $3.40 compared with $2.80 last year. By category within CAG, IDEXX VetLab consumables were $387,813 thousand, reference laboratory services $362,725 thousand, and CAG Diagnostics capital instruments $51,479 thousand. Water revenue was $54,297 thousand and LPD revenue was $33,944 thousand.

Year‑to‑date operating cash flow was strong at $826,045 thousand. The company repurchased $979,190 thousand of common stock year‑to‑date and ended with cash and cash equivalents of $208,166 thousand. Borrowings under the Credit Facility totaled $455,000 thousand, and total debt (current and long‑term) was $524,822 thousand as of quarter‑end. Shares outstanding were 79,851,330 on October 29, 2025.